AzTrials
AzTrials

Intracerebral HemorrhageNCT04877184

Feasibility Study of Transcranial Ultrasound Stimulation (TUS) on Stroke Patients

A study testing Transcranial ultrasound stimulation and rehabilitation and Rehabilitation in people with Intracerebral Hemorrhage and Hemiplegia, run by Cheng-Hsin General Hospital at 1 site in Taiwan.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Currently, the main treatment method for Intracerebral Hemorrhage (ICH) is medication or surgery. However, the effectiveness of medicines is moderate and there are several side effects. Read more about this study

Who is it for?
Ages 20 to 65 years
Conditions the study is for
Intracerebral Hemorrhage, Hemiplegia
What is being tested?
Transcranial ultrasound stimulation and rehabilitation and Rehabilitation
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
20 participants
Where
1 siteTaiwan
Study dates
8 Jul 2021to 31 Dec 2024
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 20 to 65 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Age between 20 and 65 years old
  • hemiplegia or hemiparesis
  • has a history of hypertension
  • a victim of first episode of hypertensive intracerebral hemorrhage at basal ganglion
  • 3 to 12 months after the episode of hypertensive intracerebral hemorrhage
  • medically stable
  • the blood flow of middle cerebral artery (M1) could be detected by transcranial doppler

Who cannot join

  • severe heart failure (New York Heart Association class 4)
  • severe angina pectoris (canadian cardiovascular society class 4)
  • chronic kidney disease stage 5
  • hepatic encephalopathy stage 2 or more advanced
  • uncontrolled diabetes mellitus in recent 6 months (HbA1c > 8.5)
  • combined with intraventricular hemorrhage causing hydrocephalus and underwent ventriculoperitoneal shunt placement surgery
Show all 16Show fewer
  • high-dose radiation exposure in recent 1 year
  • blood flow of middle cerebral artery (M1) could be not be detected by transcranial doppler at either side
  • major psychological disease in recent 6 months (for example, uncontrolled depression, schizophrenia, and bipolar disease)
  • has evidence of any autoimmune disease, neurodegenerative disease (such as parkinsonism, Alzheimer's disease), or epilepsy
  • has clinically significant systemic disease or severe infection (pneumonia, sepsis)
  • pregnant or lactating women
  • allergy to MRI contrast
  • uncontrolled hypertension (systolic blood pressure higher than 160 mmHg or diastolic blood pressure higher than 100 mmHg) transcranial doppler
  • aneurysm, brain tumor, or arteriovenous malformation identified by MRA
  • has coagulation disorders or other coagulation problems identified by blood test (abnormal complete blood count, prothrombin time, or partial thromboplastin time)

Trial locations and contacts

1 site in 1 country.

Taiwan1 site, 1 recruiting
  • Cheng-Hsin general hospital

    Taipei

    Wen-Shin Song, +886-2-28264400 ext. 2081, ch6364@chgh.org.tw

    Recruiting

Other trials in Taiwan

About this study

Currently, the main treatment method for Intracerebral Hemorrhage (ICH) is medication or surgery. However, the effectiveness of medicines is moderate and there are several side effects. In this clinical trial, we would like to enhance the protein levels of brain derived neurotrophic factor in the brain by the transcranial ultrasound stimulation (TUS). By this technology, the symptoms of ICH could be alleviated and the side effects of medicines might be avoided. Preclinical trials have also shown that low-intensity pulsed ultrasound can alleviate the degree of neuroinflammation, neurodegeneration and significantly improve motor and cognitive deficits after brain injury. The purpose of this clinical trial is to evaluate the safety and feasibility of TUS for the treatment of patients with hypertensive intracerebral hemorrhage. The primary safety assessment indexes are brain magnetic resonance imaging (MRI) and brain magnetic resonance angiography (MRA). The secondary safety assessment indexes include weight, vital signs, electrocardiogram, general blood biochemical tests, adverse reaction events, and concurrent drug tracking. The feasibility assessment includes blood specific biomarker expression and neurological function \& quality of life scales.

Being tested
Transcranial ultrasound stimulation and rehabilitation, Rehabilitation
Medical subject headings
Cerebral Hemorrhage, Hemiplegia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Transcranial ultrasound stimulation and rehabilitationDevice

    The participants in experimental group would received transcranial ultrasound stimulation and rehabilitation therapy.

    • transcranial ultrasound stimulation: during 4 weeks
    • rehabilitation: physiotherapy and occupational therapy (may combine with speech therapy and psychological therapy if needed)
  • RehabilitationDevice

    The participants in control group would received rehabilitation therapy.

    • rehabilitation: physiotherapy and occupational therapy (may combine with speech therapy and psychological therapy if needed)
Study groups in NCT04877184
Study groupRoleWhat they receive
Transcranial ultrasound stimulation and rehabilitationExperimentalThe investigators expect to enroll 10 people in the experimental group.
Receives: Device: Transcranial ultrasound stimulation and rehabilitation
RehabilitationActive comparatorThe investigators expect to enroll 10 people in the control group.
Receives: Device: Rehabilitation

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Brain observation by image

    The investigators would use Magnetic Resonance Image (MRI) to observe if there is brain atrophy, hemorrhage, or any other anatomical change in brain. Magnetic Resonance Angiography (MRA) would be used, too, to observe any change in intracerebral vessels or blood-brain barrier.

    Measured: 12 weeks

Secondary outcomes (17)
  1. Body weight

    As a safety parameter, the investigators would follow up body weight (in kilograms) of the subjects, to observe if there is a tendency to rise or descend.

    Measured: 12 weeks

  2. respiratory rate

    As a safety parameter, the investigators would follow up respiratory rate (in times per minute) of the subjects, to observe if there is a tendency to rise or descend.

    Measured: 12 weeks

  3. blood pressure

    As a safety parameter, the investigators would follow up blood pressure (in millimeter of mercury, mmHg) of the subjects, to observe if there is a tendency to rise or descend.

    Measured: 12 weeks

  4. heart rate

    As a safety parameter, the investigators would follow up heart rate (in times per minute) of the subjects, to observe if there is a tendency to rise or descend.

    Measured: 12 weeks

  5. electrocardiogram

    As a safety parameter, the investigators would follow up electrocardiogram of the subjects, to observe if some newly-onset pathological evidences occur. For example, ST segment elevation, ST segment dumping, Q wave, or left bundle branch block could be pathological findings.

    Measured: 12 weeks

  6. Serum biomarkers: trophic factors

    The investigators would measure serum brain-derived neurotrophic factor (BDNF) and serum vascular endothelial growth factor (VEGF) as the indicators as trophic factors. The changes of these biomarkers during the study would be evaluated.

    Measured: 12 weeks

  7. Serum biomarkers: factors relating inflammatory response

    The investigators would measure matrix metalloproteinase-9, S100 calcium-binding protein B, glial fibrillary acidic protein, and Interleukin, as the factors relating inflammatory response. The changes of these biomarkers during the study would be evaluated.

    Measured: 12 weeks

  8. Serum biomarkers: neurodegeneration

    The investigators would measure phosphorylated Tau, and β-amyloid, as the indicators of neurodegeneration. The changes of these biomarkers during the study would be evaluated.

    Measured: 12 weeks

  9. Device and procedure related adverse events recording

    Rate of adverse events following each treatment through end of study clinical evaluation

    Measured: 12 weeks

  10. National Institutes of Health Stroke Scale (NIHSS)

    National Institutes of Health Stroke Scale (NIHSS) is an objective scale for neurologic impairment of stoke. This scale includes 13 categories, with highest score of 3 or 4 and lowest score is 0, quantifying level of consciousness, best gaze, visual filed, facial palsy, motor function, limb ataxia, sensory function, language function, dysarthria, extinction/inattention. The maximum score is 42, which signifies severe stroke, while the minimum score is 0, meaning a normal exam.

    Measured: 12 weeks

  11. Stroke Rehabilitation Assessment of Movement (STREAM)

    Stroke Rehabilitation Assessment of Movement (STREAM) evaluate the recovery of voluntary movement and mobility post stroke in supine, sitting, and standing posture. It is composed of 30 items, measuring the upper limb voluntary movement, lower limb voluntary movements and basic mobility. A 3 point original scale (0~2) is used for upper and lower limb voluntary movement, and a 4 point original scale (0~3) is used for basic mobility. Higher scales means better motor performance.

    Measured: 12 weeks

  12. Fugl-Meyer Assessment (FMA)

    The Fugl-Meyer Assessment (FMA) assesses motor functioning, balance, sensation and joint functioning in patients with post-stroke hemiplegia. The investigators chose the domain of motor score for this study. The motor score ranges from 0 (hemiplegia) to 100 points (normal motor performance). Divided into 66 points for upper extremity and 34 points for the lower extremity.

    Measured: 12 weeks

  13. Wolf Motor Function test (WMFT)

    It is a 17-item measure used to quantify upper extremity functional limitations. It is comprised of 2 strength items and 15 timed task performance items, and the investigators choose the 15 timed task performance items for this study. The test yields 3 scores: a functional ability (FA) score, which quantifies quality of performance; a timed (time) score, quantifying speed of performance in seconds; and a grip strength (strength) score. The FA score uses a 6-point ordinal scale to rate movement quality on 15 items, where 0 indicates no attempt to use the more affected upper extremity and 5 indicates that movement of the affected upper extremity appears to be normal. The time score is the mean time to complete the same 15 items; scores were truncated at 120 seconds.

    Measured: 12 weeks

  14. Berg Balance Scale (BBS)

    Berg balance scale determines a patient's ability to safely balance during a series of predetermined tasks. It is a 14 item list with each item consisting of a five-point ordinal scale ranging from 0 to 4, with 0 indicating the lowest level of function and 4 the highest level of function.

    Measured: 12 weeks

  15. Timed up-and-go test

    Time up-and-go test assesses a person's mobility and requires both static and dynamic balance. During this test, a person should stand up from a chair and walk for 3 meters, turns around and walks back to the chair and sit down. The spent time was recorded.

    Measured: 12 weeks

  16. Barthal index

    The Barthel Index measures a person's performance in activities of daily living (ADL). Ten variables describing ADL and mobility are scored, a higher number being a reflection of greater ability to function independently. The Barthel Index consists of 10 items of mobility and self care ADL.

    Measured: 12 weeks

  17. World Health Organization Quality of Life (WHOQOL-BREF)-Taiwan version

    The World Health Organization Quality of Life (WHOQOL-BREF) is a 28-item instrument consisting of four domains: physical health (7 items), psychological health (6 items), social relationships (4 items), and environmental health (9 items); with another 2 items about general condition and overall quality of life. Each individual item of the WHOQOL-BREF is scored from 1 to 5 on a response scale, which is stipulated as a five-point ordinal scale. The scores are then transformed linearly to a 0-100-scale. The higher scores equals better quality of life.

    Measured: 12 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted7 May 2021
  2. Study start8 Jul 2021
  3. Primary completion31 Dec 2023 (estimated)
  4. Study completion31 Dec 2024 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Non-randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Investigator, Outcomes assessor
Enrolment
20 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04877184
Sponsor's protocol ID
(785)109A-24
Status last verified
Mar 2023
First submitted
27 Apr 2021
Last updated
7 Mar 2023
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing Transcranial ultrasound stimulation and rehabilitation and Rehabilitation in people with Intracerebral Hemorrhage and Hemiplegia, run by Cheng-Hsin General Hospital at 1 site in Taiwan.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 16 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 7 Mar 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Wen-Shin Song (+886-2-28264400 ext. 2081, ch6364@chgh.org.tw), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Brain observation by image (time frame: 12 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Mar 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in